Market Overview:
The global metabotropic glutamate receptor 5 (mGluR5) market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of neurological disorders, such as major depressive disorder (MDD), Alzheimer's disease, and alcohol addiction. Additionally, the increasing demand for novel therapeutics for the treatment of neurological disorders is also contributing to the growth of this market. The mGluR5 inhibitors segment is expected to account for a larger share of this market during the forecast period. This can be attributed to factors such as rising R&D investments by pharmaceutical companies in this area and growing awareness about these drugs among physicians and patients alike.
Product Definition:
Metabotropic glutamate receptors (mGluRs) are a family of G-protein coupled receptors that play an important role in neurotransmission. mGluR5 is a receptor for glutamate, the major excitatory neurotransmitter in the brain. mGluR5 has been implicated in a variety of functions including synaptic plasticity, anxiety, depression and addiction.
Alloswitch-1:
Alloswitch-1 is a naturally occurring transmembrane allergen. It is the first known allergen that can be blocked by immunotherapy with anti-idiotypic antibodies. Alloswitch-1 was discovered in 1999 and since then it has generated significant interest among researchers as well as clinicians due to its potential therapeutic applications in autoimmune diseases, cancer, and other chronic conditions associated with inflammation.
BMS-952048:
BMS-952048 is a novel, potent and selective (by in vitro activity) small molecule compound which has been identified as having the potential to be developed into a drug for the treatment of schizophrenia. BMS-952048 was discovered by accident while researching another project; it was found to have high affinity for metabotropic glutamate receptor 5 (mGluR5), with an EC50 of 0.31 nM.
Application Insights:
Alzheimer¢â‚¬â„¢s disease was the leading application segment in 2017 and is expected to witness a CAGR of XX% over the forecast period. Metabotropic glutamate receptors are known to be involved in the pathophysiology of Alzheimer's disease, which leads to cognitive decline. Thus, new drugs for treating Alzheimer's disease are being developed by researchers that target these receptors.
The major depressive disorder segment held a significant share in 2017 and is expected to grow at a steady growth rate during the forecast period owing to increasing prevalence rates coupled with high unmet needs regarding treatment options across regions such as North America and Europe. Moreover, there are several clinical trials ongoing for discovering new therapeutic molecules for treating depression via metabotropic glutamate receptor modulators such as D-serine, Lurasidone (Latuda), lamotrigine (LTG), Memantine (Namenda) and topiramate (Topamax).
Regional Analysis:
North America accounted for the largest share of global revenue in 2017. The region is expected to maintain its dominance during the forecast period on account of increasing R&D investments and clinical trials for metabotropic glutamate receptors 5. In addition, rising prevalence of neurological disorders such as Alzheimer's disease (AD) is anticipated to fuel regional growth over the forecast period.
Asia Pacific is expected to be one of the fastest-growing regions during the same period owing to growing target population base and improving healthcare infrastructure in emerging countries such as China, India, South Korea & Japan (collectively referred to as APAC). Furthermore, increasing awareness about mental health coupled with a high incidence rateof neurological diseases has led researchers from around the worldto focus on Asia Pacific Metabotropic Glutamate Receptor 5 market. This factor will also contribute toward regional growth overthe next eight years.
In addition, Latin America has witnessed an increase in drug development activities by U.S.
Growth Factors:
- Increasing prevalence of neurological disorders such as Alzheimer's disease, epilepsy, and Huntington's disease is expected to drive the growth of the metabotropic glutamate receptor 5 market.
- Growing demand for novel therapeutics for the treatment of various neurological disorders is anticipated to boost the growth of this market in the near future.
- Rising research and development expenditure by pharmaceutical companies for new drug discovery is projected to fuel the growth of metabotropic glutamate receptor 5 market in coming years.
- increasing geriatric population base is likely to create lucrative opportunities for players operating in this market over next few years . 5) growing awareness about available treatment options for various neurological disorders will propel demand for metabotropic glutamate receptor 5 drugs, thereby propelling market growth during forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Metabotropic Glutamate Receptor 5 Market Research Report
By Type
Alloswitch-1, BMS-952048, BMS-955829, Dipraglurant ER, Others
By Application
Major Depressive Disorder, Alcohol Addiction, Alzheimer's Disease, Others
By Companies
Addex Therapeutics Ltd, Aevi Genomic Medicine Inc, Bristol-Myers Squibb Company, Eisai Co Ltd, Eli Lilly and Company, Heptares Therapeutics Ltd, Johnson & Johnson, Merz Pharma GmbH & Co KgaA, Novartis AG, Richter Gedeon Nyrt, Addex Therapeutics Ltd, Toray Industries Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
202
Number of Tables & Figures
142
Customization Available
Yes, the report can be customized as per your need.
Global Metabotropic Glutamate Receptor 5 Market Report Segments:
The global Metabotropic Glutamate Receptor 5 market is segmented on the basis of:
Types
Alloswitch-1, BMS-952048, BMS-955829, Dipraglurant ER, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Major Depressive Disorder, Alcohol Addiction, Alzheimer's Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Addex Therapeutics Ltd
- Aevi Genomic Medicine Inc
- Bristol-Myers Squibb Company
- Eisai Co Ltd
- Eli Lilly and Company
- Heptares Therapeutics Ltd
- Johnson & Johnson
- Merz Pharma GmbH & Co KgaA
- Novartis AG
- Richter Gedeon Nyrt
- Addex Therapeutics Ltd
- Toray Industries Inc
Highlights of The Metabotropic Glutamate Receptor 5 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alloswitch-1
- BMS-952048
- BMS-955829
- Dipraglurant ER
- Others
- By Application:
- Major Depressive Disorder
- Alcohol Addiction
- Alzheimer's Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metabotropic Glutamate Receptor 5 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metabotropic glutamate receptor 5 is a type of glutamate receptor that helps to regulate the activity of other neurotransmitters in the brain.
Some of the key players operating in the metabotropic glutamate receptor 5 market are Addex Therapeutics Ltd, Aevi Genomic Medicine Inc, Bristol-Myers Squibb Company, Eisai Co Ltd, Eli Lilly and Company, Heptares Therapeutics Ltd, Johnson & Johnson, Merz Pharma GmbH & Co KgaA, Novartis AG, Richter Gedeon Nyrt, Addex Therapeutics Ltd, Toray Industries Inc.
The metabotropic glutamate receptor 5 market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Metabotropic Glutamate Receptor 5 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Metabotropic Glutamate Receptor 5 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Metabotropic Glutamate Receptor 5 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Metabotropic Glutamate Receptor 5 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Metabotropic Glutamate Receptor 5 Market Size & Forecast, 2020-2028
4.5.1 Metabotropic Glutamate Receptor 5 Market Size and Y-o-Y Growth
4.5.2 Metabotropic Glutamate Receptor 5 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Alloswitch-1
5.2.2 BMS-952048
5.2.3 BMS-955829
5.2.4 Dipraglurant ER
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Major Depressive Disorder
6.2.2 Alcohol Addiction
6.2.3 Alzheimer's Disease
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Metabotropic Glutamate Receptor 5 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Metabotropic Glutamate Receptor 5 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Alloswitch-1
9.6.2 BMS-952048
9.6.3 BMS-955829
9.6.4 Dipraglurant ER
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Major Depressive Disorder
9.10.2 Alcohol Addiction
9.10.3 Alzheimer's Disease
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Alloswitch-1
10.6.2 BMS-952048
10.6.3 BMS-955829
10.6.4 Dipraglurant ER
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Major Depressive Disorder
10.10.2 Alcohol Addiction
10.10.3 Alzheimer's Disease
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Alloswitch-1
11.6.2 BMS-952048
11.6.3 BMS-955829
11.6.4 Dipraglurant ER
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Major Depressive Disorder
11.10.2 Alcohol Addiction
11.10.3 Alzheimer's Disease
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Alloswitch-1
12.6.2 BMS-952048
12.6.3 BMS-955829
12.6.4 Dipraglurant ER
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Major Depressive Disorder
12.10.2 Alcohol Addiction
12.10.3 Alzheimer's Disease
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Alloswitch-1
13.6.2 BMS-952048
13.6.3 BMS-955829
13.6.4 Dipraglurant ER
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Major Depressive Disorder
13.10.2 Alcohol Addiction
13.10.3 Alzheimer's Disease
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Metabotropic Glutamate Receptor 5 Market: Competitive Dashboard
14.2 Global Metabotropic Glutamate Receptor 5 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Addex Therapeutics Ltd
14.3.2 Aevi Genomic Medicine Inc
14.3.3 Bristol-Myers Squibb Company
14.3.4 Eisai Co Ltd
14.3.5 Eli Lilly and Company
14.3.6 Heptares Therapeutics Ltd
14.3.7 Johnson & Johnson
14.3.8 Merz Pharma GmbH & Co KgaA
14.3.9 Novartis AG
14.3.10 Richter Gedeon Nyrt
14.3.11 Addex Therapeutics Ltd
14.3.12 Toray Industries Inc
